These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31144334)

  • 1. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).
    Atreya C; Glynn S; Busch M; Kleinman S; Snyder E; Rutter S; AuBuchon J; Flegel W; Reeve D; Devine D; Cohn C; Custer B; Goodrich R; Benjamin RJ; Razatos A; Cancelas J; Wagner S; Maclean M; Gelderman M; Cap A; Ness P
    Transfusion; 2019 Sep; 59(9):3002-3025. PubMed ID: 31144334
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward universal pathogen reduction of the blood supply (Conference Report, p. 3002).
    Marks P; Verdun N
    Transfusion; 2019 Sep; 59(9):3026-3028. PubMed ID: 31218709
    [No Abstract]   [Full Text] [Related]  

  • 3. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic issues currently facing the US blood system.
    Fredrick J; Berger JJ; Menitove JE
    Transfusion; 2020 May; 60(5):1093-1096. PubMed ID: 32339298
    [No Abstract]   [Full Text] [Related]  

  • 5. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop.
    Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA
    Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century.
    Glynn SA; Busch MP; Dodd RY; Katz LM; Stramer SL; Klein HG; Simmons G; Kleinman SH; Shurin SB;
    Transfusion; 2013 Feb; 53(2):438-54. PubMed ID: 22690676
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathogen reduced plasma products: a clinical practice scientific review from the AABB.
    Cushing MM; Pagano MB; Jacobson J; Schwartz J; Grossman BJ; Kleinman S; Han MA; Cohn CS;
    Transfusion; 2019 Sep; 59(9):2974-2988. PubMed ID: 31268584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efforts Toward Elimination of Infectious Agents in Blood Products.
    Jacquot C; Delaney M
    J Intensive Care Med; 2018 Oct; 33(10):543-550. PubMed ID: 29562814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion. Blood cleansing deemed safe, but more donors required.
    AIDS Policy Law; 2002 Aug; 17(16):8. PubMed ID: 12236221
    [No Abstract]   [Full Text] [Related]  

  • 11. The negative secondary test for bacterial contamination: reducing the risk of septic transfusion reactions from platelets.
    Tomasulo PA; Jacobs MR
    Transfusion; 2017 Aug; 57(8):2054-2055. PubMed ID: 28656692
    [No Abstract]   [Full Text] [Related]  

  • 12. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.
    Picker SM
    Blood Transfus; 2013 Jul; 11(3):343-8. PubMed ID: 23522896
    [No Abstract]   [Full Text] [Related]  

  • 13. Serious hazards of transfusion - conference report: celebration of 20 years of UK haemovigilance.
    Bolton-Maggs PHB
    Transfus Med; 2017 Dec; 27(6):393-400. PubMed ID: 29282809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of the blood supply--time to raise the bar.
    Snyder EL; Stramer SL; Benjamin RJ
    N Engl J Med; 2015 May; 372(20):1882-5. PubMed ID: 25902384
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevention of bacterial risk: pathogen inactivation/detection of bacteria].
    Morel P; Naegelen C; Deschaseaux M; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):109-14. PubMed ID: 23622837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.
    Walsh GM; Shih AW; Solh Z; Golder M; Schubert P; Fearon M; Sheffield WP
    Transfus Med Rev; 2016 Apr; 30(2):53-68. PubMed ID: 26962008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA: A tough tonic.
    Wadman M
    Nature; 2009 Nov; 462(7272):406-7. PubMed ID: 19940894
    [No Abstract]   [Full Text] [Related]  

  • 18. The usefulness of pathogen inactivation during an outbreak of the new strain of influenza (H1N1).
    Narimatsu H; Yuji K; Shimodaira S; Kami M
    Transfus Med Rev; 2010 Apr; 24(2):151-2. PubMed ID: 20303039
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    Di Minno G; Navarro D; Perno CF; Canaro M; Gürtler L; Ironside JW; Eichler H; Tiede A
    Ann Hematol; 2017 Aug; 96(8):1253-1270. PubMed ID: 28624906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety.
    Leach Bennett J; Blajchman MA; Delage G; Fearon M; Devine D
    Transfus Med Rev; 2011 Oct; 25(4):267-92. PubMed ID: 21763103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.